KPF
MIST icon

K2 Principal Fund’s Milestone Pharmaceuticals MIST Stock Holding History

K2 Principal Fund’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-169,730
Closed -$642K – 269
2020
Q2 		$642K Buy
+169,730
New +$547K 0.1% 160

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

K2 Principal Fund's MIST Position: Q3 2020 in Review

K2 Principal Fund sold out of Milestone Pharmaceuticals (MIST) in Q3 2020, closing a stake of 169,730 shares — an estimated $642K sold.

K2 Principal Fund first reported a position in MIST in Q2 2020 and held it in 1 quarter. The position peaked at $642K in Q2 2020. 31 funds tracked by Wall St. Rank hold MIST as of Q3 2020.

  • K2 Principal Fund reported no remaining Milestone Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • K2 Principal Fund sold 169,730 Milestone Pharmaceuticals shares in Q3 2020, an estimated $642K.
  • K2 Principal Fund first reported a position in Milestone Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • K2 Principal Fund's Milestone Pharmaceuticals position peaked at $642K in Q2 2020.
  • 31 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q3 2020.

Based on K2 Principal Fund's 13F filing for Q3 2020, filed 13 Nov 2020.